$CRKN
Crown Electrokinetics Corp. Stock $crkn

$crkn Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022048134 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.160M	$3.002M	$3.471M
YoY Change	-55.6%	-39.49%	-20.34%
% of Gross Profit
Research & Development	$955.0K	$1.473M	$1.096M
YoY Change	21.35%	238.62%	21.08%
% of Gross Profit
Depreciation & Amortization	$69.00K	$68.00K	$107.0K
YoY Change	-4.17%	257.89%	149.77%
% of Gross Profit
Operating Expenses	$3.115M	$4.475M	$4.567M
YoY Change	-44.89%	-17.07%	-13.22%
Operating Profit	-$3.115M	-$4.475M	-$4.567M
YoY Change	-44.89%	-17.07%	-13.22%
Interest Expense	$1.000K	$2.000K	-$3.000K
YoY Change	-150.0%	0.0%	-99.49%
% of Operating Profit
Other Income/Expense, Net	-$1.000K	-$2.000K	-$3.000K
YoY Change	-97.96%	0.0%	-99.71%
Pretax Income	-$3.116M	-$4.477M	-$4.570M
YoY Change	-45.36%	-17.06%	-77.89%
Income Tax
% Of Pretax Income
Net Earnings	-$3.116M	-$4.477M	-$4.570M
YoY Change	-45.36%	-17.06%	-77.89%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.18	-$0.27
Diluted Earnings Per Share	-$0.18	-$0.27	-$288.2K
COMMON SHARES
Basic Shares Outstanding	15.87M shares	273.8K shares	15.86M shares
Diluted Shares Outstanding	17.64M shares	16.42M shares	15.86M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$342.0K	$984.0K	$2.513M
YoY Change	-96.47%	-92.11%	-83.57%
Cash & Equivalents	$342.0K	$984.0K	$2.513M
Short-Term Investments
Other Short-Term Assets	$380.0K	$683.0K	$774.0K
YoY Change	-46.1%	167.84%	123.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$722.0K	$1.667M	$3.287M
YoY Change	-93.06%	-86.91%	-78.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.416M	$1.092M	$3.069M
YoY Change	192.56%	297.09%	1367.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$403.0K	$403.0K	$402.0K
YoY Change	1339.29%	1289.66%	1873.49%
Total Long-Term Assets	$5.444M	$5.301M	$5.186M
YoY Change	137.21%	177.98%	175.99%
TOTAL ASSETS
Total Short-Term Assets	$722.0K	$1.667M	$3.287M
Total Long-Term Assets	$5.444M	$5.301M	$5.186M
Total Assets	$6.166M	$6.968M	$8.473M
YoY Change	-51.45%	-52.4%	-51.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.211M	$840.0K	$330.0K
YoY Change	184.27%	161.68%	15.73%
Accrued Expenses	$133.0K	$116.0K	$597.0K
YoY Change	-72.29%	11.54%	183.07%
Deferred Revenue
YoY Change
Short-Term Debt	$8.000K	$8.000K	$8.000K
YoY Change	-98.18%	-98.18%	-98.18%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.605M	$2.400M	$935.0K
YoY Change	19.33%	177.78%	0.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.815M	$1.815M	$1.814M
YoY Change
Total Long-Term Liabilities	$1.815M	$1.815M	$1.814M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.605M	$2.400M	$935.0K
Total Long-Term Liabilities	$1.815M	$1.815M	$1.814M
Total Liabilities	$3.420M	$4.215M	$2.749M
YoY Change	154.28%	387.85%	194.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$85.85M	-$82.74M
YoY Change
Common Stock	$2.000K	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.746M	$2.753M	$5.724M
YoY Change
Total Liabilities & Shareholders Equity	$6.166M	$6.968M	$8.473M
YoY Change	-51.45%	-52.4%	-51.64%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.116M	-$4.477M	-$4.570M
YoY Change	-45.36%	-17.06%	-77.89%
Depreciation, Depletion And Amortization	$69.00K	$68.00K	$107.0K
YoY Change	-4.17%	257.89%	149.77%
Cash From Operating Activities	-$2.106M	-$2.391M	-$3.552M
YoY Change	-15.69%	-12.67%	19.42%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$254.0K	-$65.00K
YoY Change	-95.66%	198.82%	-95.73%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$20.00K	-$254.0K	-$65.00K
YoY Change	-95.66%	198.82%	-95.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.484M	1.116M
YoY Change	715.38%	27800.0%
NET CHANGE
Cash From Operating Activities	-2.106M	-2.391M	-3.552M
Cash From Investing Activities	-20.00K	-254.0K	-65.00K
Cash From Financing Activities	1.484M	1.116M
Net Change In Cash	-642.0K	-1.529M	$0.00
YoY Change	-76.88%	-45.76%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.106M	-$2.391M	-$3.552M
Capital Expenditures	-$20.00K	-$254.0K	-$65.00K
Free Cash Flow	-$2.086M	-$2.137M	-$3.487M
YoY Change	2.41%	-19.45%	140.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1110 NE Circle Blvd.
CY2021Q4	us-gaap	Assets Assets	9652000	usd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Corvallis
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OR
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	97330
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	674-3612
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	840000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	358000	usd
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	116000	usd
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15874624	shares
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	298000	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	378000	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39924
	dei	Entity Registrant Name EntityRegistrantName	Crown Electrokinetics Corp.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5423944
CY2022Q2	us-gaap	Assets Assets	6968000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82737000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73690000	usd
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	CRKN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	984000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6130000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	683000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	687000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1667000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	6817000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1092000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	895000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1709000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1761000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2097000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	403000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	179000	usd
CY2022Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	1058000	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2400000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	664000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1815000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4215000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	664000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14614627	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14530126	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85489000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	82677000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5396000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2753000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9042000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10658000	usd
	us-gaap	Other Income OtherIncome	-6000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	2000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	2000	usd
CY2022Q2	crkn	Stock Issue Duringperiod Value Issuance Of Common Stock Atthemarket Offering Net Of Offering Costs StockIssueDuringperiodValueIssuanceOfCommonStockAtthemarketOfferingNetOfOfferingCosts	58000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8988000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6968000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9652000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1473000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	435000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2568000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1340000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3002000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4961000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6474000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9318000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4475000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5396000	usd
	us-gaap	Operating Expenses OperatingExpenses	9042000	usd
	us-gaap	Operating Expenses OperatingExpenses	10658000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4475000	usd
	us-gaap	Interest Expense InterestExpense	5000	usd
	us-gaap	Interest Expense InterestExpense	533000	usd
	crkn	Loss On Exchange Of Notes Payable For Common Stock And Warrants LossOnExchangeOfNotesPayableForCommonStockAndWarrants	6000	usd
	crkn	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans	13805000	usd
	crkn	Change In Fair Value Of Warrants Liability ChangeInFairValueOfWarrantsLiability	-1024000	usd
	crkn	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-51000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15413000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5398000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9047000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26071000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16419699	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14315142	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16139564	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13241786	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	5724000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1000	usd
CY2022Q2	crkn	Stockbased Compensation StockbasedCompensation	1448000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000	usd
	crkn	Issuance Of Common Stock To Consultants IssuanceOfCommonStockToConsultants	247000	usd
	crkn	Stockbased Compensation StockbasedCompensation	5802000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2753000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16587000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	244000	usd
CY2021Q2	crkn	Stock Issued During The Period Stock Option Exercise StockIssuedDuringThePeriodStockOptionExercise	4000	usd
CY2021Q2	crkn	Stockbased Compensation StockbasedCompensation	2339000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5398000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	13776000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8988000	usd
	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC	223000	usd
	crkn	Stock Issue Duringperiod Value Issuance Of Common Stock Atthemarket Offering Net Of Offering Costs StockIssueDuringperiodValueIssuanceOfCommonStockAtthemarketOfferingNetOfOfferingCosts	58000	usd
	crkn	Stockbased Compensation StockbasedCompensation	2531000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9047000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2753000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-6771000	usd
	crkn	Issuance Of Common Stock And Warrants Net Of Fees IssuanceOfCommonStockAndWarrantsNetOfFees	19326000	usd
	crkn	Issuance Of Common Stock And Preferred Stock In Connection With Conversion Of Notes IssuanceOfCommonStockAndPreferredStockInConnectionWithConversionOfNotes	19222000	usd
	crkn	Repurchased Beneficial Conversion Feature In Connection With Conversion Of Notes Payable RepurchasedBeneficialConversionFeatureInConnectionWithConversionOfNotesPayable	-6647000	usd
	crkn	Issuance Of Common Stock Warrants In Connection With Note Exchange Agreements IssuanceOfCommonStockWarrantsInConnectionWithNoteExchangeAgreements	4918000	usd
	crkn	Exercise Of Common Stock Warrants ExerciseOfCommonStockWarrants	180000	usd
	crkn	Stock Issued During The Period Stock Option Exercise StockIssuedDuringThePeriodStockOptionExercise	4000	usd
	crkn	Stock Issued During Period Value Of Reclassification Of Warrant Liabilities StockIssuedDuringPeriodValueOfReclassificationOfWarrantLiabilities	3566000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26071000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	13776000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9047000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26071000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2531000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5802000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	247000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	234000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	112000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13805000	usd
	crkn	Loss On Exchange Of Notes Payables For Common Stock And Warrants LossOnExchangeOfNotesPayablesForCommonStockAndWarrants	6000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	458000	usd
	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-1024000	usd
	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability	-51000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	239000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	30000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	370000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-862000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-182000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-253000	usd
	crkn	Increase Decrease In Accrued Interest IncreaseDecreaseInAccruedInterest	72000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-143000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12442000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6130000	usd
CY2022Q1	crkn	Irrevocable Standby Letter Of Credit IrrevocableStandbyLetterOfCredit	10000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5943000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5639000	usd
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	258000	usd
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	162000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	61000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1475000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-319000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1637000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19326000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	60000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	1058000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	180000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	233000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	25000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1116000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19718000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5146000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	984000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12478000	usd
	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC	223000	usd
	crkn	Issuance Of Common Stock And Preferred Stock In Connection With Conversion Of Note IssuanceOfCommonStockAndPreferredStockInConnectionWithConversionOfNote	19222000	usd
	crkn	Repurchase Beneficial Conversion Feature In Connection With Conversion Of Notes Payable RepurchaseBeneficialConversionFeatureInConnectionWithConversionOfNotesPayable	6647000	usd
	crkn	Reclassifications Of Warrant Liabilities ReclassificationsOfWarrantLiabilities	3566000	usd
	crkn	Issuance Of Common Stock Warrants In Connection With Note Exchange Agreement IssuanceOfCommonStockWarrantsInConnectionWithNoteExchangeAgreement	4918000	usd
	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	112000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
	crkn	Accumulated Deficit AccumulatedDeficit	82700000	usd
CY2022Q2	crkn	Working Capital WorkingCapital	700000	usd
	crkn	Net Loss NetLoss	9000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	5900000	usd
CY2022Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.12	pure
CY2022Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	50000	shares
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	1000000	usd
CY2022Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	5000000	usd
CY2022Q1	crkn	Aggregate Gross Proceed Percentage AggregateGrossProceedPercentage	0.03	pure
CY2022Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	51169	shares
	crkn	Agreement Of Sales AgreementOfSales	57574	usd
	us-gaap	Payments For Commissions PaymentsForCommissions	2124	usd
	crkn	Share Based Compensation Arrangement By Share Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	1.17
	crkn	Basis Of Presentationa And Principles Of Consolidation BasisOfPresentationaAndPrinciplesOfConsolidation	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results for the full year or the results for any future periods. These condensed financial statements should be read in conjunction with the audited financial statements and related notes for the fiscal year ended December 31, 2021 included in the Company’s Form 10-KT filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17080898	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18962914	shares
CY2022Q2	us-gaap	Depreciation Depreciation	68000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	19000	usd
	us-gaap	Depreciation Depreciation	121000	usd
	us-gaap	Depreciation Depreciation	35000	usd
	crkn	Consideration Paid Amount ConsiderationPaidAmount	264000	usd
	us-gaap	Legal Fees LegalFees	38000	usd
CY2016Q1	crkn	Intellectual Property Description IntellectualPropertyDescription	the Company, entered into an IP agreement with HP to acquire a research license to determine the feasibility of incorporating HP’s electro-kinetic display technology in the Company’s products. Under the terms of the agreement, the license is to be used for research purposes only, has a purchase price of $200,000 for the technology and a two-year closing date. On April 12, 2016 the Company and HP entered into the first amendment to the agreement, which reduced the purchase price of the technology to $175,000. The sales agreement entered into with HP concurrently with the first amendment to the agreement allocated $25,000 of the $200,000 purchase price to acquire equipment to be used in the research. On May 1, 2017, the Company and HP entered into the second amendment to the agreement which increased the purchase price for the technology to $375,000 and extended the closing date to January 31, 2020. On March 10, 2019, the Company and HP entered into the third amendment to the agreement, which extended the closing date to January 31, 2021, enumerated certain intellectual property owned by HP that is not subject to the exclusive license granted to the Company and revised the schedule of fees payable by the Company to HP. Under the terms of the fourth amendment with HP (see details below), $75,000 will be included in the purchase price for the option to purchase assignable patents, which was paid on February 9, 2021.
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	375000	usd
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2021Q1	crkn	Intellectual Property Agreement Description IntellectualPropertyAgreementDescription	On February 4, 2021, the Company entered into the fourth amendment to the IP agreement with HP. Under the terms of the amendment, the parties agreed to amend the list of patent and patent applications, which includes two additional patents that are assignable to the Company by HP. The Company exercised the option to purchase the assignable patents and paid HP $1.55 million dollars on February 9, 2021. Upon assignment of the patents, the Company will pay HP a royalty fee based on the cumulative gross revenue received by the Company from the patents as follows: 1. Prior to December 31, 2029: ● Less than $70,000,000, royalty rate of 0.00% ● $70,000,000 - $500,000,000, royalty rate of 1.25% ● $500,000,000 and beyond, royalty rate of 1.00% 2. After January 1, 2030 and onward, royalty rate of 0.00% Under the terms of the amendment, HP waived any interest that would have been accrued on the open payable of $75,000 which was due from the Company related to the license agreement dated January 31, 2016.
CY2022Q2	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1800000	usd
CY2021Q4	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1739000	usd
CY2022Q2	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2021Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2175000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2114000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	466000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	353000	usd
CY2022Q2	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1709000	usd
CY2021Q4	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1761000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	60000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	47000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	113000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	77000	usd
CY2022Q2	crkn	General Liability Insurance GeneralLiabilityInsurance	15000	usd
CY2021Q4	crkn	General Liability Insurance GeneralLiabilityInsurance	234000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	101000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	7000	usd
CY2021Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	57000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	116000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	298000	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Shares Issued SharesIssued	5333333	shares
CY2020Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P10Y
CY2020Q4	us-gaap	Plan Of Reorganization Description Of Equity Securities Issued Or To Be Issued PlanOfReorganizationDescriptionOfEquitySecuritiesIssuedOrToBeIssued	The available shares in the 2020 Plan will automatically increase on the first trading day in January of each calendar year during the term of this Plan, commencing with January 2021, by an amount equal to the lesser of (i) five percent (5%) of the total number of shares of common stock issued and outstanding on December 31 of the immediately preceding calendar year, (ii) 1,000,000 shares of common stock or (iii) such number of shares of common stock as may be established by the Company’s Board of Directors.
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.917	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.50	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.917	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.50	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0325	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0325	pure
CY2017Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800	usd
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	The lease expired on June 30, 2018 and the Company extended the lease through June 30, 2019.
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4500	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7550	usd
CY2020Q3	us-gaap	Other Operating Income OtherOperatingIncome	23097	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	652776	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.5
	crkn	Vested Stock Option VestedStockOption	1476670	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	600000	usd
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	33332	shares
	crkn	Restricted Stock Award Forfeituress RestrictedStockAwardForfeituress	33332	shares
	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	200000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4525177	shares
CY2021Q4	crkn	Weighted Average Exercise Price Beginning Outstanding WeightedAverageExercisePriceBeginningOutstanding	2.65
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7088000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	200000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4725177	shares
CY2022Q2	crkn	Weighted Average Exercise Price Ending Outstanding WeightedAverageExercisePriceEndingOutstanding	2.62
	crkn	Weighted Average Remaining Contractual Tenn Years Ending Outstanding WeightedAverageRemainingContractualTennYearsEndingOutstanding	P3Y6M
CY2022Q2	crkn	Aggregate Intrinsic Value Ending Outstanding AggregateIntrinsicValueEndingOutstanding	611000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1175913	shares
	crkn	Weighted Average Exercise Price Exercisable WeightedAverageExercisePriceExercisable	0.33
	crkn	Weighted Average Remaining Contractual Tenn Years Exercisable WeightedAverageRemainingContractualTennYearsExercisable	P3Y7M6D
	crkn	Aggregate Intrinsic Value Exercisable AggregateIntrinsicValueExercisable	611000	usd
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400	usd
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200	usd
CY2020Q3	us-gaap	Investment Company Shareholder Service Fee Expense InvestmentCompanyShareholderServiceFeeExpense	11979	usd
CY2020Q3	us-gaap	Payments For Fees PaymentsForFees	11118	usd
CY2021Q3	us-gaap	Other Operating Income OtherOperatingIncome	23805	usd
CY2021Q3	us-gaap	Investment Company Shareholder Service Fee Expense InvestmentCompanyShareholderServiceFeeExpense	12337	usd
CY2021Q3	us-gaap	Payments For Fees PaymentsForFees	11468	usd
	crkn	Lease Agreement Description LeaseAgreementDescription	the Company entered into the seventh amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 576 square feet of cubicle space, 1096 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11. Effective September 1, 2021, the quarterly operating expense will be $31,647 covering all utility and facility tooling costs. The sublease is extended until June 30, 2025.
CY2022Q1	crkn	Lease Agreement Description LeaseAgreementDescription	the Company entered into the eighth amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 768 square feet of cubicle space, 2,088 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11. Effective January 24, 2022, the quarterly operating expense will be $44,252 covering all utility and facility tooling costs.
CY2022Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-06-30
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2200000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2100000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	190000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	380000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	11000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	16000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	201000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	396000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	189000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	341000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2336000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q2	crkn	Operating Leases Future Minimum Payments Nine Months OperatingLeasesFutureMinimumPaymentsNineMonths	379000	usd
CY2022Q2	crkn	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent	776000	usd
CY2022Q2	crkn	Operating Leases Future Minimum Payment Due In Four Years OperatingLeasesFutureMinimumPaymentDueInFourYears	678000	usd
CY2022Q2	crkn	Operating Leases Future Minimum Payment Due In Five Years OperatingLeasesFutureMinimumPaymentDueInFiveYears	475000	usd
CY2022Q2	crkn	Operating Leases Future Minimum Payment Due In Six Years OperatingLeasesFutureMinimumPaymentDueInSixYears	390000	usd
CY2022Q2	crkn	Operating Leases Future Minimum Payments Due Six Months Thereafter OperatingLeasesFutureMinimumPaymentsDueSixMonthsThereafter	57000	usd
CY2022Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2755000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	562000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2193000	usd
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	200000	usd
CY2021Q2	us-gaap	Payments For Rent PaymentsForRent	100000	usd
	us-gaap	Payments For Rent PaymentsForRent	400000	usd
	us-gaap	Payments For Rent PaymentsForRent	100000	usd
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	crkn	Series A Preferred Stock SeriesAPreferredStock		usd
CY2021Q4	crkn	Series B Preferred Stock Value SeriesBPreferredStockValue		usd
CY2021Q4	crkn	Series C Preferred Stock Value SeriesCPreferredStockValue		usd
	us-gaap	Other Income OtherIncome		usd
	crkn	Loss On Exchange Of Notes Payable For Common Stock And Warrants LossOnExchangeOfNotesPayableForCommonStockAndWarrants		usd
	crkn	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans		usd
	crkn	Change In Fair Value Of Warrants Liability ChangeInFairValueOfWarrantsLiability		usd
	crkn	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16419699	shares
	crkn	Delivery Of Restricted Common Stock DeliveryOfRestrictedCommonStock		usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	crkn	Canceled Restricted Stocks Awards CanceledRestrictedStocksAwards		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	crkn	Loss On Exchange Of Notes Payables For Common Stock And Warrants LossOnExchangeOfNotesPayablesForCommonStockAndWarrants		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	crkn	Increase Decrease In Accrued Interest IncreaseDecreaseInAccruedInterest		usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	crkn	Issuance Of Common Stock And Preferred Stock In Connection With Conversion Of Note IssuanceOfCommonStockAndPreferredStockInConnectionWithConversionOfNote		usd
	crkn	Repurchase Beneficial Conversion Feature In Connection With Conversion Of Notes Payable RepurchaseBeneficialConversionFeatureInConnectionWithConversionOfNotesPayable		usd
	crkn	Reclassifications Of Warrant Liabilities ReclassificationsOfWarrantLiabilities		usd
	crkn	Issuance Of Common Stock Warrants In Connection With Note Exchange Agreement IssuanceOfCommonStockWarrantsInConnectionWithNoteExchangeAgreement		usd
	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q2	us-gaap	Accrued Rent Current AccruedRentCurrent		usd
CY2022Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001761696

Files In Submission

Name	View Source	Status
0001213900-22-048134-index-headers.html	Edgar Link	pending
0001213900-22-048134-index.html	Edgar Link	pending
0001213900-22-048134.txt	Edgar Link	pending
0001213900-22-048134-xbrl.zip	Edgar Link	pending
crkn-20220630.xsd	Edgar Link	pending
f10q0622ex31-1_crownelectro.htm	Edgar Link	pending
f10q0622ex31-2_crownelectro.htm	Edgar Link	pending
f10q0622ex32-1_crownelectro.htm	Edgar Link	pending
f10q0622ex32-2_crownelectro.htm	Edgar Link	pending
f10q0622_crownelectro.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
crkn-20220630_cal.xml	Edgar Link	unprocessable
crkn-20220630_pre.xml	Edgar Link	unprocessable
crkn-20220630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crkn-20220630_def.xml	Edgar Link	unprocessable
f10q0622_crownelectro_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRKN
Crown Electrokinetics Corp. Stock $crkn

2022 Q3 Form 10-Q Financial Statement

#000121390022048134 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN Crown Electrokinetics Corp. Stock $crkn

2022 Q3 Form 10-Q Financial Statement

#000121390022048134 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN
Crown Electrokinetics Corp. Stock $crkn